The 8 most recent market catalysts affecting $PDSB, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 85
PDS Biotechnology Announces Publication Of Results From Phase 2 Trial Evaluating PDS0101, HPV16-Targeted Immunotherapy, In Combination With Pembrolizumab In JAMA Oncology, Peer Reviewed Journal Of American Medical Association
PDS Biotechnology announced the publication of Phase 2 trial results for PDS0101 in JAMA Oncology, a highly respected peer-reviewed journal. The key finding of a 39.3 months median…
Sep 15, 2026
Corporate Catalyst
Bullish
Impact 85
PDS Biotech Stock Surges Tuesday: What's Driving the Action?
PDS Biotechnology announced the initial closing of a PIPE financing, securing $11.3 million, with a potential additional $11 million upon achieving a key clinical milestone. This c…
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 75
PDS Biotech shares are trading higher. The company announced initial closing of up to $22.3 million PIPE financing.
This headline indicates a significant positive development for PDS Biotech. PIPE (Private Investment in Public Equity) financing provides capital directly from institutional invest…
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 75
PDS Biotechnology shares are trading higher after the company announced it raised up to $22.55 million in equity funding in a Private Investment in Public Equity transaction.
This headline is a strong corporate catalyst for PDS Biotechnology. The successful Private Investment in Public Equity (PIPE) transaction provides crucial capital for the company, …
Sep 8, 2026
Corporate Catalyst
Neutral
Impact 75
PDS Biotechnology Announces Up To $22.55M PIPE Led By Nant Capital, With About $11.55M At Initial Closing Expected September 11
This headline represents a significant corporate catalyst for PDS Biotechnology. The substantial PIPE financing provides crucial capital for the company, likely funding ongoing res…
Aug 25, 2026
Corporate Catalyst
Bearish
Impact 75
PDS Biotechnology Intends To Cut Workforce By 36%; Removes Stephan Toutain As COO, Effective Aug. 21
PDS Biotechnology is implementing a substantial workforce reduction of 36% and has removed its COO, Stephan Toutain, effective August 21. This move signals a significant operationa…
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 92
PDS Biotechnology Q2 EPS $(0.18) Misses $(0.13) Estimate
PDS Biotechnology (PDSB) announced Q2 earnings per share of $(0.18), which was a substantial miss compared to the analyst consensus estimate of $(0.13). This 38.46% miss, despite b…
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 75
PDS Biotechnology Announces Strategic Refocus To Prioritize PDS0301 In Metastatic Colorectal Cancer; Expects To Advance PDS0301 Through Randomized Phase 2B Development Program Over Next 18 To 24 Months
PDS Biotechnology has announced a significant strategic shift, halting internal investment in its PDS0101 Phase 3 trial and actively seeking partnerships for its continued developm…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.